ReviewOncology letters2026
Soluble isoforms of EGFR family in breast cancer: Advances and clinical relevance (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BrCa) is the leading cause of cancer death among women worldwide. The epidermal growth factor receptor (EGFR) family, consisting of EGFR/erythroblastic leukemia viral (v-erbB) oncogene homolog (ErbB)1, human epidermal growth factor receptor (HER)2/ErbB2, HER3/ErbB3 and HER4/ErbB4, serves a pivotal role in BrCa pathogenesis. In addition to the membrane-bound forms, soluble isoforms of these receptors have emerged as biologically and clinically significant players in BrCa. These soluble variants are produced either through alternative splicing or proteolytic cleavage of the extracellular domain. Functionally, soluble EGFR family members can act as decoy receptors or interfere with receptor homo- or heterodimerization, ultimately disrupting downstream signaling cascades and contributing to the dysregulated growth and survival of BrCa cells. Notably, soluble EGFR and HER2 are detectable in the serum of patients with BrCa, and their serum levels fluctuate during disease progression and treatment. These dynamic serum fluctuations possess strong prognostic and predictive potential. This review summarized the current understanding of soluble EGFR family members in BrCa, including their mechanisms of generation and biological functions. The clinical relevance of soluble EGFR and the shed extracellular domain of HER2 in BrCa is addressed, with an emphasis on their emerging roles as diagnostic biomarkers and promising therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.